Investor Presentaiton
iSPOT UPDATE
Brain Resource®
.
•
BACKGROUND & CURRENT STATUS
iSPOT-D (International Study To Predict Optimized Treatment in Depression) was a clinical trial to identify objective predictors of
treatment response to 3 of the most-commonly used anti-depressants: Escitalopram (Lexapro), Sertraline (Zoloft), and Venlafaxine-
XR (Effexor)
660 genetic variants or "SNPs" from 1,008 patients' bloods were analyzed (cognitive, brain imaging and genetics data)
While the current business plan has been focused on the development of MBS (Total Brain), BRC has engaged in a low-energy/high-
potential-return project to complete genetics data acquisition
•
•
.
The initial scientific analysis with 850k SNPs from a Genome-Wide Association Study was completed according to plan
The initial findings suggest positive results for the predictive ability of the iSPOT algorithms for the 3 iSPOT drugs together (i.e. based on
the iSPOT test, a patient can find out if any 1 of the 3 drugs will work for them or not)
The next step, currently in process, is validating if the same is true for each of the 3 drugs individually (i.e. if the iSPOT test can help a
patient find out if which one of the 3 drugs, specifically, will be effective for them)
The healthcare investment bank hired to assist with evaluating the strategic alternatives for iSPOT, including licensing,
commercialization, and M&A, has continued outreach to potential partners within 4 main verticals: (i.) diagnostics, (ii.) genomics,
(iii.) pharmaceuticals, and (iv.) drug development
11 have expressed initial interest to-date and next steps are largely dependent on the findings of the subsequent phase of scientific
analysis
©2018 BRAIN RESOURCE LTD.
CONFIDENTIAL MATERIAL ALL RIGHTS RESERVED 24View entire presentation